NCT03922100View on ClinicalTrials.gov

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

August 29, 2024

Study Completion Date

August 29, 2024

Conditions
Acute Myeloid Leukemia (AML)Chronic Myelomonocytic Leukemia (CMML)
Interventions
DRUG

NMS-03592088

Route of administration: Oral

Trial Locations (11)

20089

Istituto Clinico Humanitas, Rozzano

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

24127

ASST Papa Giovanni XXIII, Bergamo

25123

ASST Spedali Civili di Brescia, Brescia

33604

CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Pessac

40138

Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna

44000

Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes

46026

Hospital Universitari i Politècnic La Fe, Valencia

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

72037

Centre Hospitalier du Mans, Le Mans

00168

Fondazione Policlinico Universitario Agostino Gemelli, Roma

Sponsors
All Listed Sponsors
lead

Nerviano Medical Sciences

INDUSTRY

NCT03922100 - Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Biotech Hunter | Biotech Hunter